Orofacial Abscess due to *Candida dubliniensis*: An Extensive Infection Caused by A Rare Yeast

*Candida dubliniensis*e bağlı Orofasiyal Apse: Nadir Bir Mayanın Neden Olduğu Yaygın Bir Enfeksiyon

Chuan Hun Ding¹, Asrul Abdul Wahab¹, Toh Leong Tan², Salamah Faisal Ummu³

¹Department of Medical Microbiology & Immunology, Faculty of Medicine, Universiti Kebangsaan Malaysia, Kuala Lumpur, Malaysia
²Department of Emergency Medicine, Faculty of Medicine, Universiti Kebangsaan Malaysia, Kuala Lumpur, Malaysia
³Faculty of Medicine & Defence Health, Universiti Pertahanan Nasional Malaysia, Kuala Lumpur, Malaysia

ABSTRACT

*Candida dubliniensis* is a pathogenic yeast which is rarely encountered in clinical practice. An 83-year-old HIV-negative woman with numerous medical co-morbidities presented with a dental abscess which was preceded by a long-standing toothache. The right side of her face was swollen from the preauricular to the malar and submandibular regions. A computed tomography scan revealed a masseteric abscess with air pockets extending to the right temporalis muscle. She underwent two separate incision and drainage procedures, performed one week apart. A yeast which formed branched pseudohyphae with thick-walled triplet terminal chlamydospores was cultured from her pus specimen. The yeast was identified biochemically as *C. dubliniensis*. However, before any antifungal agent could be administered, the patient succumbed to her illness.

Key Words: *Candida dubliniensis*, fluconazole, orofacial abscess, terminal chlamydospores

Received: 02.19.2020

Accepted: 10.20.2020

ÖZET

*Candida dubliniensis*, klinik pratikte nadiren karşılaşılan patojenik bir mayadır. Çok sayıda tıbbi komorbiditesi olan 83 yaşındaki HIV negatif bir kadın, öncesinde uzun süredir devam eden bir diş ağrısı olan diş apsesi ile başvurdu. Yüzünün sağ tarafları kulak önünden malar ve submandibüler bölgelere doğru şişmişti. Bilgisayarlı tomografi taraması, sağ temporal kasına uzanan hava çeperi olan masseterik apse ortaya çıktı. Bir hafta arayla iki ayrı kesicilik ve drenaj prosedürü uygulandı. Kalın duvarlı üçlü terminal klamidosporlar ile dalı psödohifalar oluşturmuş bir maya, irin önünden kültürlandı. Maya biyokimyasal olarak *C. dubliniensis* olarak tanımlanmıştı. Bunun birlikte, herhangi bir antifungal ajan uygulanamadı, hasta kaybedilmiştir.

Anahtar Sözcüklər: *Candida dubliniensis*, flukonazol, orofasiyal apse, terminal klamidosporlar

Geliş Tarihi: 19.02.2020

Kabul Tarihi: 20.10.2020

ORCID IDs: C.H.D. 0000-0001-6040-219X, A.A.W. 0000-0001-8283-6028, T.L.T. 0000-0002-6771-0141, S.F.U. 0000-0003-4383-6986

Address for Correspondence / Yazışma Adresi: Ding Chuan Hun, MD Department of Medical Microbiology & Immunology, Preclinical Building, Faculty of Medicine, Universiti Kebangsaan Malaysia, 56000 Cheras, Kuala Lumpur, Malaysia. E-mail: dingch@ppukm.ukm.edu.my

©Telâf Hakki 2021 Gazi Üniversitesi Tıp Fakültesi - Makale metnine http://medicaljournal.gazi.edu.tr/ web adresinden ulaşılabilir.

©Copyright 2021 by Gazi University Medical Faculty - Available on-line at web site http://medicaljournal.gazi.edu.tr/
doi:http://dx.doi.org/10.12996/gmj.2021.24
INTRODUCTION

Candida dubliniensis was first reported in 1995, when it was isolated from the oral cavities of Irish HIV-positive individuals (1). Although it is classified as a non-albicans Candida (NAC) species, it shares similar traits with Candida albicans (2). However, compared to C. albicans, the prevalence of C. dubliniensis is very low, with studies reporting isolation rates of >60% for the former, but <3% for the latter (3). The designation of any yeast as a NAC is not merely of academic interest, because NACs such as Candida krusei and Candida auris are notorious for being fluconazole-resistant (4,5). C. dubliniensis in particular has caused concern with its inducible fluconazole resistance (3). Although the gamut of infections caused by C. dubliniensis is wide, most are limited to the oral cavity and systemic infections (e.g. candidemia) are rare (2). We report a case of a dental abscess caused by C. dubliniensis which progressed to become an extensive orofacial abscess that ultimately led to the demise of the patient.

CASE REPORT

An 83-year-old HIV-negative Chinese woman with multiple medical co-morbidities (e.g. poorly controlled diabetes mellitus, chronic renal impairment and congestive heart failure) presented to the emergency department of UKM Medical Centre with a two-day history of right facial pain and swelling. She had been having a right-sided toothache for the past three months which became complicated by a dental abscess. On examination, her body temperature was 37.6 °C, indicating a low-grade fever. The right side of her face was visibly swollen, tender and erythematous. The swelling was firm and fluctuant, and extended from the preauricular to the malar and submandibular regions. Crepitus was also palpable on the right temporal region. A computed tomography scan revealed a right masseteric abscess with air pockets extending to the right temporalis muscle (Figure 1).

She then underwent incision and drainage (I&D) of the right masticator and buccal space abscesses together with tooth extraction. IV amoxicillin-clavulanate 1.5 g q8h was commenced empirically. However, a week post I&D the patient’s swelling was still apparent. Thus, a second I&D was attempted and 20 ml of pus was drained from the temporal space. This time, a yeast was cultured from the pus specimen. The yeast formed branched pseudohyphae with dense verticils of blastoconidia and thick-walled triplet terminal chlamydospores (Figure 2) after 24-48 h of cornmeal agar culture at 30 °C, suggesting C. dubliniensis. Biochemical identification using the VITEK 2 YST card (bioMerieux, France) confirmed the yeast’s identity as C. dubliniensis with a 93% probability (bionumber: 6003544061301370). Antifungal susceptibility testing was then performed using the broth microdilution kit Sensititre YeastOne YO10 (Thermo Scientific, USA) and the antifungal minimal inhibitory concentration (MIC) values are presented in Table 1. However, before any antifungal could be administered, the patient succumbed to her illness. Up to the time of her demise, her blood cultures were persistently negative for bacterial and fungal organisms.
Ann Clin Lab Sci 2019; 42 (2): 120-122

The timely detection of any pathogen aids patient management by permitting targeted antimicrobial therapy to be commenced early. The antymycotic susceptibility profile of C. dubliniensis is generally favourable, with susceptibility rates between 76-100%, depending on the antifungal agent (8). Specifically, fluconazole susceptibility is as high as 86% (8). Consistent with what has been reported, our own C. dubliniensis isolate had low antifungal MIC values, inferring that it had no drug resistance issues. Thus, if C. dubliniensis can be presumptively identified early, fluconazole therapy can also be started early (i.e. before formal antifungal susceptibility results are ready). However, the patient should preferably be “fluconazole-naïve”, because of inducible fluconazole resistance in C. dubliniensis (3).

CONCLUSION
Cornmeal cultures should be undertaken in all candidiasis cases, particularly if the infection originates from or involves the oral cavity. The presence of triplet terminal chlamydomycoses presumptively identifies C. dubliniensis. Definitive identification should then be achieved through a commercially available biochemical yeast identification kit or platform. Any of the commonly prescribed antifungal agents may be employed for treatment, including fluconazole, provided the patient has not been previously exposed to this drug.

Conflicts of interest
No conflict of interest was declared by the authors.

REFERENCES
1. Sullivan DJ, Westerneng TJ, Haynes KA, Bennett DE, Coleman DC. Candida dubliniensis sp. nov.: phenotypic and molecular characterization of a novel species associated with oral candidiasis in HIV-infected individuals. Microbiology 1995; 141: 1507-21.
2. Sullivan DJ, Moran GP, Pinjon E, Al-Mosaid A, Stokes C, Vaughan C, et al. Comparison of the epidemiology, drug resistance mechanisms, and virulence of Candida dubliniensis and Candida albicans. FEMS Yeast Res 2004; 4: 369-76.
3. Yang CW, Barkham TM, Chan FY, Wang Y. Prevalence of Candida species, including Candida dubliniensis, in Singapore. J Clin Microbiol 2003; 41: 472-4.
4. Ding CH, Situ SF, Steven A, Razak MFA. The pitfall of utilizing a commercial biochemical yeast identification kit to detect Candida auris. Ann Clin Lab Sci 2019; 49: 546-9.
5. Ding CH, Zaki Z. Mixed non-albicans Candida fungemia: an uncommon but easily overlooked clinical entity. Asian J Pharm Clin Res 2018; 11: 8-10.
6. Vilela MM, Kamei K, Sano A, Tanaka R, Uno J, Takahashi I, et al. Pathogenicity and virulence of Candida dubliniensis: comparison with C. albicans. Med Mycol 2002; 40: 249-57.
7. Ellis R, Kock JL, Pohl CH. Candida albicans or Candida dubliniensis? Mycoses 2011; 54: 1-16.
8. Quintdós G, Carrillo-Muñoz AJ, Arévalo MP, Salgado J, Alonso-Vargas R, Rodrigo JM, et al. In vitro susceptibility of Candida dubliniensis to current and new antifungal agents. Chemotherapy 2000; 46: 395-401.

Table 1. Antifungal MIC values for C. dubliniensis

| Antifungal agent     | MIC value (µg/ml) |
|----------------------|------------------|
| Amphotericin B       | 0.25             |
| Fluconazole          | 0.25             |
| Itraconazole         | 0.06             |
| Voriconazole         | 0.03             |
| Posaconazole         | 0.03             |
| Micafungin           | 0.06             |
| Anidulafungin        | 0.12             |
| Caspofungin          | 0.12             |
| 5-flucytosine        | 0.25             |

MIC, minimal inhibitory concentration

DISCUSSION
It is believed that C. dubliniensis is considerably less virulent than the more commonly isolated C. albicans (2,6). Although both are among the few Candida species endowed with the ability to form true hyphae (an important virulence determinant) in vitro, the ability of the former to do so in vivo appears to be impaired (2). Moreover, the former is more susceptible to the fungicidal activity of human leukocytes than the latter (6). Consistent with the published literature, our patient’s candidiasis was also localized to the oral and facial regions, as evidenced by her persistently negative blood cultures. Thus, our patient’s demise was likely to have occurred due to the deleterious combination of the infection itself with her advanced age and various medical co-morbidities. A history of retroviral infection need not necessary be present for the infection to set in, as our patient was HIV-negative.

An early clue to the presence of C. dubliniensis can be sought from cornmeal cultures, in which the yeast forms pairs or triplets of chlamydomycoses terminally at the end of short branched pseudohyphae (1). In contrast, the phenotypically similar C. albicans forms single terminal chlamydomycoses. Apart from cornmeal agar morphology, growth at 42°C can also assist in distinguishing C. albicans from C. dubliniensis, with only the former having the ability to grow at elevated temperatures (7). For our yeast isolate, we did not attempt to culture it at 42°C because we had already confirmed its identity through biochemical testing (i.e. VITEK 2 identification).

The timely detection of any pathogen aids patient management by permitting targeted antimicrobial therapy to be commenced early. The antymycotic susceptibility profile of C. dubliniensis is generally favourable, with susceptibility rates between 76-100%, depending on the antifungal agent (8). Specifically, fluconazole susceptibility is as high as 86% (8). Consistent with what has been reported, our own C. dubliniensis isolate had low antifungal MIC values, inferring that it had no drug resistance issues. Thus, if C. dubliniensis can be presumptively identified early, fluconazole therapy can also be started early (i.e. before formal antifungal susceptibility results are ready). However, the patient should preferably be “fluconazole-naïve”, because of inducible fluconazole resistance in C. dubliniensis (3).

CONCLUSION
Cornmeal cultures should be undertaken in all candidiasis cases, particularly if the infection originates from or involves the oral cavity. The presence of triplet terminal chlamydomycoses presumptively identifies C. dubliniensis. Definitive identification should then be achieved through a commercially available biochemical yeast identification kit or platform. Any of the commonly prescribed antifungal agents may be employed for treatment, including fluconazole, provided the patient has not been previously exposed to this drug.

Conflict of interest
No conflict of interest was declared by the authors.

REFERENCES
1. Sullivan DJ, Westerneng TJ, Haynes KA, Bennett DE, Coleman DC. Candida dubliniensis sp. nov.: phenotypic and molecular characterization of a novel species associated with oral candidiasis in HIV-infected individuals. Microbiology 1995; 141: 1507-21.
2. Sullivan DJ, Moran GP, Pinjon E, Al-Mosaid A, Stokes C, Vaughan C, et al. Comparison of the epidemiology, drug resistance mechanisms, and virulence of Candida dubliniensis and Candida albicans. FEMS Yeast Res 2004; 4: 369-76.
3. Yang CW, Barkham TM, Chan FY, Wang Y. Prevalence of Candida species, including Candida dubliniensis, in Singapore. J Clin Microbiol 2003; 41: 472-4.
4. Ding CH, Situ SF, Steven A, Razak MFA. The pitfall of utilizing a commercial biochemical yeast identification kit to detect Candida auris. Ann Clin Lab Sci 2019; 49: 546-9.
5. Ding CH, Zaki Z. Mixed non-albicans Candida fungemia: an uncommon but easily overlooked clinical entity. Asian J Pharm Clin Res 2018; 11: 8-10.
6. Vilela MM, Kamei K, Sano A, Tanaka R, Uno J, Takahashi I, et al. Pathogenicity and virulence of Candida dubliniensis: comparison with C. albicans. Med Mycol 2002; 40: 249-57.
7. Ellis R, Kock JL, Pohl CH. Candida albicans or Candida dubliniensis? Mycoses 2011; 54: 1-16.
8. Quintdós G, Carrillo-Muñoz AJ, Arévalo MP, Salgado J, Alonso-Vargas R, Rodrigo JM, et al. In vitro susceptibility of Candida dubliniensis to current and new antifungal agents. Chemotherapy 2000; 46: 395-401.